🚀 VC round data is live in beta, check it out!
Syngene Valuation Multiples
Discover revenue and EBITDA valuation multiples for Syngene and similar public comparables like VCANBIO, ST Pharm, Granules India, Fagron and more.
Syngene Overview
About Syngene
Syngene International Ltd is a contract research and manufacturing organization in India. It supports research and development programs, from lead generation to clinical and commercial supplies. The Company is engaged in a single operating segment of providing contract research and manufacturing services. The company operates in India, the United States of America and other countries, of which a majority of the revenue is derived from the USA. The company receives revenue by providing contract research and manufacturing services. It offers services such as Oligonucleotide synthesis, Bioinformatics, Clinical development services, polymer research, chemical development, safety assessment, discovery chemistry, discovery biology, and others.
Founded
1993
HQ
Employees
8.2K
Website
Financials (LTM)
EV
$2B
Syngene Financials
Syngene reported last 12-month revenue of $399M and EBITDA of $94M.
In the same LTM period, Syngene generated $297M in gross profit, $94M in EBITDA, and $35M in net income.
Revenue (LTM)
Syngene P&L
In the most recent fiscal year, Syngene reported revenue of $427M and EBITDA of $123M.
Syngene expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $399M | XXX | $427M | XXX | XXX | XXX |
| Gross Profit | $297M | XXX | $278M | XXX | XXX | XXX |
| Gross Margin | 75% | XXX | 65% | XXX | XXX | XXX |
| EBITDA | $94M | XXX | $123M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 29% | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $35M | XXX | $56M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | 13% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Syngene Stock Performance
Syngene has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Syngene's stock price is $4.71.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.2% | XXX | XXX | XXX | $0.14 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSyngene Valuation Multiples
Syngene trades at 4.6x EV/Revenue multiple, and 19.5x EV/EBITDA.
EV / Revenue (LTM)
Syngene Financial Valuation Multiples
As of April 21, 2026, Syngene has market cap of $2B and EV of $2B.
Equity research analysts estimate Syngene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Syngene has a P/E ratio of 54.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 4.6x | XXX | 4.3x | XXX | XXX | XXX |
| EV/EBITDA | 19.5x | XXX | 14.9x | XXX | XXX | XXX |
| EV/EBIT | 33.8x | XXX | 25.1x | XXX | XXX | XXX |
| EV/Gross Profit | 6.2x | XXX | 6.6x | XXX | XXX | XXX |
| P/E | 54.5x | XXX | 33.7x | XXX | XXX | XXX |
| EV/FCF | 214.0x | XXX | 42.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Syngene Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Syngene Margins & Growth Rates
Syngene's revenue in the last 12 month grew by 14%.
Syngene's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Syngene's rule of 40 is 36% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Syngene's rule of X is 54% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Syngene Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | (7%) | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | (24%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 36% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 54% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 18% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 50% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Syngene Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing and Life Sciences Tools comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Syngene | XXX | XXX | XXX | XXX | XXX | XXX |
| VCANBIO | XXX | XXX | XXX | XXX | XXX | XXX |
| ST Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Granules India | XXX | XXX | XXX | XXX | XXX | XXX |
| Fagron | XXX | XXX | XXX | XXX | XXX | XXX |
| Piramal Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Syngene M&A Activity
Syngene acquired XXX companies to date.
Last acquisition by Syngene was on XXXXXXXX, XXXXX. Syngene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Syngene
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSyngene Investment Activity
Syngene invested in XXX companies to date.
Syngene made its latest investment on XXXXXXXX, XXXXX. Syngene invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Syngene
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Syngene
| When was Syngene founded? | Syngene was founded in 1993. |
| Where is Syngene headquartered? | Syngene is headquartered in India. |
| How many employees does Syngene have? | As of today, Syngene has over 8K employees. |
| Who is the CEO of Syngene? | Syngene's CEO is Peter Bains. |
| Is Syngene publicly listed? | Yes, Syngene is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Syngene? | Syngene trades under SYNGENE ticker. |
| When did Syngene go public? | Syngene went public in 2015. |
| Who are competitors of Syngene? | Syngene main competitors are VCANBIO, ST Pharm, Granules India, Fagron. |
| What is the current market cap of Syngene? | Syngene's current market cap is $2B. |
| What is the current revenue of Syngene? | Syngene's last 12 months revenue is $399M. |
| What is the current revenue growth of Syngene? | Syngene revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of Syngene? | Current revenue multiple of Syngene is 4.6x. |
| Is Syngene profitable? | Yes, Syngene is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Syngene? | Syngene's last 12 months EBITDA is $94M. |
| What is Syngene's EBITDA margin? | Syngene's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Syngene? | Current EBITDA multiple of Syngene is 19.5x. |
| What is the current FCF of Syngene? | Syngene's last 12 months FCF is $9M. |
| What is Syngene's FCF margin? | Syngene's last 12 months FCF margin is 2%. |
| What is the current EV/FCF multiple of Syngene? | Current FCF multiple of Syngene is 214.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.